Literature DB >> 28600743

[Ataxias and hereditary spastic paraplegias].

R Schüle1,2, L Schöls3,4.   

Abstract

Hereditary ataxias and spastic paraplegias are genetic disorders with age-dependent nearly complete penetrance. The mostly monogenetic etiology allows one to establish the diagnosis, study pathogenesis and to develop new causative therapeutic approaches for these diseases. Both the causative genes as well as the clinical presentation overlap considerably between hereditary ataxias and spastic paraplegias. This strongly argues towards a united classification for these two groups of diseases. Next generation sequencing technologies have greatly expanded the number of genes known to be causative for hereditary ataxias and spastic paraplegias and allow simultaneous time- and cost-effective diagnostic testing of > 200 genes. However, repeat expansions and large genomic deletions must be considered separately. Here, we suggest a pragmatic algorithm for genetic testing in hereditary ataxias and spastic paraplegias that we have developed in our specialized outpatient clinics. Detailed phenotyping remains crucial to interpret the multitude of genetic variants discovered by high throughput sequencing techniques. Despite recent technical advances, a substantial proportion of ataxia and spastic paraplegia families are still without a molecular diagnosis. Beside new and so far undetected ataxia and spasticity genes, unusual mutation types including noncoding variants and polygenic inheritance patterns may contribute. Because of these clinical, genetic, and technological challenges, patients with hereditary ataxias and spastic paraplegias should be referred to specialized centers offering research and clinical studies. This will also help to recruit representative patient cohorts for upcoming interventional trials.

Entities:  

Keywords:  Gene sequencing; Genetic testing; Genetic variants; Hereditary spastic paraplegia; Phenotype; Spinocerebellar ataxia

Mesh:

Year:  2017        PMID: 28600743     DOI: 10.1007/s00115-017-0357-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  39 in total

1.  Atlastin1 mutations are frequent in young-onset autosomal dominant spastic paraplegia.

Authors:  Alexandra Dürr; Agnès Camuzat; Emilie Colin; Chantal Tallaksen; Didier Hannequin; Paula Coutinho; Bertrand Fontaine; Annick Rossi; Roger Gil; Christophe Rousselle; Merle Ruberg; Giovanni Stevanin; Alexis Brice
Journal:  Arch Neurol       Date:  2004-12

Review 2.  Genetics of the dominant ataxias.

Authors:  Dineke S Verbeek; Bart P C van de Warrenburg
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

3.  The Spastic Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity.

Authors:  R Schüle; T Holland-Letz; S Klimpe; J Kassubek; T Klopstock; V Mall; S Otto; B Winner; L Schöls
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

4.  Classification of the hereditary ataxias and paraplegias.

Authors:  A E Harding
Journal:  Lancet       Date:  1983-05-21       Impact factor: 79.321

5.  Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).

Authors:  Alejandro Estrada-Cuzcano; Shaun Martin; Teodora Chamova; Matthis Synofzik; Dagmar Timmann; Tine Holemans; Albena Andreeva; Jennifer Reichbauer; Riet De Rycke; Dae-In Chang; Sarah van Veen; Jean Samuel; Ludger Schöls; Thorsten Pöppel; Danny Mollerup Sørensen; Bob Asselbergh; Christine Klein; Stephan Zuchner; Albena Jordanova; Peter Vangheluwe; Ivailo Tournev; Rebecca Schüle
Journal:  Brain       Date:  2017-02       Impact factor: 13.501

6.  High frequency of partial SPAST deletions in autosomal dominant hereditary spastic paraplegia.

Authors:  C Beetz; A O H Nygren; J Schickel; M Auer-Grumbach; K Bürk; G Heide; J Kassubek; S Klimpe; T Klopstock; F Kreuz; S Otto; R Schüle; L Schöls; A-D Sperfeld; O W Witte; T Deufel
Journal:  Neurology       Date:  2006-10-11       Impact factor: 9.910

7.  Friedreich's ataxia. Revision of the phenotype according to molecular genetics.

Authors:  L Schöls; G Amoiridis; H Przuntek; G Frank; J T Epplen; C Epplen
Journal:  Brain       Date:  1997-12       Impact factor: 13.501

8.  Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA).

Authors:  Michael C Kruer; Coro Paisán-Ruiz; Nathalie Boddaert; Moon Y Yoon; Hiroko Hama; Allison Gregory; Alessandro Malandrini; Randall L Woltjer; Arnold Munnich; Stephanie Gobin; Brenda J Polster; Silvia Palmeri; Simon Edvardson; John Hardy; Henry Houlden; Susan J Hayflick
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

9.  Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy.

Authors:  Stephan Klebe; Christel Depienne; Sylvie Gerber; Georges Challe; Mathieu Anheim; Perrine Charles; Estelle Fedirko; Elodie Lejeune; Julien Cottineau; Alfredo Brusco; Hélène Dollfus; Patrick F Chinnery; Cecilia Mancini; Xavier Ferrer; Guilhem Sole; Alain Destée; Jean-Michel Mayer; Bertrand Fontaine; Jérôme de Seze; Michel Clanet; Elisabeth Ollagnon; Philippe Busson; Cécile Cazeneuve; Giovanni Stevanin; Josseline Kaplan; Jean-Michel Rozet; Alexis Brice; Alexandra Durr
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

10.  REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31.

Authors:  Christian Beetz; Rebecca Schüle; Tine Deconinck; Khanh-Nhat Tran-Viet; Hui Zhu; Berry P H Kremer; Suzanna G M Frints; Wendy A G van Zelst-Stams; Paula Byrne; Susanne Otto; Anders O H Nygren; Jonathan Baets; Katrien Smets; Berten Ceulemans; Bernard Dan; Narasimhan Nagan; Jan Kassubek; Sven Klimpe; Thomas Klopstock; Henning Stolze; Hubert J M Smeets; Constance T R M Schrander-Stumpel; Michael Hutchinson; Bart P van de Warrenburg; Corey Braastad; Thomas Deufel; Margaret Pericak-Vance; Ludger Schöls; Peter de Jonghe; Stephan Züchner
Journal:  Brain       Date:  2008-03-05       Impact factor: 13.501

View more
  1 in total

Review 1.  [Genetics of tremor].

Authors:  G Kuhlenbäumer; F Hopfner
Journal:  Nervenarzt       Date:  2018-04       Impact factor: 1.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.